RPL23AP21: A Potential Drug Target and Biomarker (G728481)

Target Name: RPL23AP21

NCBI ID: G728481

RPL23AP21

Other Name(s): RPL23A_1_1 | ribosomal protein L23a pseudogene 21 | Ribosomal protein L23a pseudogene 21

RPL23AP21: A Potential Drug Target and Biomarker

RPL23A_1_1, also known as RPL23AP21, is a gene located on chromosome 6p21.2 in the nucleus of the human genome. RPL23A_1_1 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The RPL23A_1_1 gene encodes a protein known as RPL23A, which is a key regulator of the Replication Protein 23 (RPL23) complex. The RPL23A complex is responsible for ensuring the accurate and efficient replication of DNA in the cell. Mutations in the RPL23A gene have been linked to various human diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key challenges in studying RPL23A mutations is their low frequency. Unlike many other gene mutations, which are typically found at high frequencies, RPL23A mutations are rare and are found in only a small percentage of the population. This has made it difficult to study the effects of these mutations and to develop effective therapies.

However, researchers have made significant progress in identifying the functional consequences of RPL23A mutations. Studies have shown that RPL23A mutations can alter the activity of RPL23A, leading to changes in the expression of genes involved in cell growth, differentiation, and stress response. These changes can have significant consequences for the health and development of the cell, and may contribute to the development of various diseases.

One of the most promising aspects of RPL23A research is the potential for targeting these mutations with drugs. By blocking the activity of RPL23A, researchers can reduce the impact of mutations on gene expression and potentially treat associated diseases.

While further research is needed to fully understand the effects of RPL23A mutations and to develop effective therapies, the potential for targeting these mutations with drugs is a promising area of research. With further study, researchers may be able to develop new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, RPL23A_1_1 is a gene that has the potential to be a drug target and biomarker for various diseases. Further research is needed to fully understand the effects of RPL23A mutations and to develop effective therapies. As research progresses, we may be able to develop new treatments for a variety of diseases.

Protein Name: Ribosomal Protein L23a Pseudogene 21

The "RPL23AP21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets